Shares of Abbott Laboratories (NYSE:ABT) ended Monday session in green amid volatile trading. The shares closed up +0.41 points or 1.00% at $41.42 with 7.76 million shares getting traded. Post opening the session at $40.85, the shares hit an intraday low of $40.77 and an intraday high of $41.52 and the price vacillated in this range throughout the day. The company has a market cap of $59.67 billion and the numbers of outstanding shares have been calculated to be 1.47 billion shares.
On Sept. 8, 2016 For the fourth consecutive year, Abbott (ABT) has been named the leading company in its industry by the Dow Jones Sustainability Index (DJSI), one of the most prestigious global benchmarks for corporate sustainability and responsibility. As the Industry Group Leader in Health Care Equipment & Services, Abbott is one of only two U.S.-based companies of the 24 recognized for leading their respective global industry groups.
The DJSI leaders are chosen from among 3,400 of the largest companies worldwide, including companies in developed and emerging markets. This is the 12th consecutive year that Abbott has been recognized for sustainability through its inclusion on the DJSI, including both the Dow Jones Sustainability World Index and North America Index.
“When I’m asked what we do at Abbott, my answer is that we help people live the best and fullest lives they can,” said Miles D. White, chairman and chief executive officer, Abbott. “The primary way we do that is by bringing high-quality healthcare products to people around the world. But we apply that same fundamental purpose to all we do as a company.”
Shares of Johnson & Johnson (NYSE:JNJ) ended Monday session in green amid volatile trading. The shares closed up +0.93 points or 0.79% at $119.16 with 7.24 million shares getting traded. Post opening the session at $117.76, the shares hit an intraday low of $117.38 and an intraday high of $119.45 and the price vacillated in this range throughout the day. The company has a market cap of $322.62 billion and the numbers of outstanding shares have been calculated to be 2.74 billion shares.
On Sept. 12, 2016 Johnson & Johnson (JNJ) announced that Janssen Vaccines & Prevention B.V. (Janssen) has completed a submission to the World Health Organization (WHO) for Emergency Use Assessment and Listing (EUAL) for its investigational preventive Ebola prime-boost vaccine regimen. The EUAL is a special procedure that can be implemented when there is an outbreak of a disease with high rates of morbidity or mortality and a lack of treatment or prevention options.
“Over the past four decades, we have seen 25 Ebola outbreaks, with the most recent in West Africa killing seven times more people than all previous outbreaks combined,” said Paul Stoffels, M.D., Chief Scientific Officer, Johnson & Johnson. “We must take action now so that a tragedy on the scale of West Africa never happens again. Having an Ebola vaccine available is critical for global preparedness. If the WHO grants an emergency use listing, this will accelerate the availability of Janssen’s investigational vaccine regimen to the international community in the event another Ebola crisis occurs.”